UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 04, 2023 09:22 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 04, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
March 09, 2023 08:40 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar to Participate at Upcoming Banking Conferences
March 08, 2023 16:05 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
February 28, 2023 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
February 15, 2023 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
November 30, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference
November 21, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
November 16, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update
November 03, 2022 08:30 ET
|
Cellectar Biosciences
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization...